NCT04432532

Brief Summary

This is a prospective study of rare neuroendocrine and adrenal tumors. Subjects will be enrolled via informed consent, and blood and/or saliva and tissue will be collected. This is designed to work in conjunction with IRB#831990 which is a retrospective protocol. The University of Pennsylvania will be a contributing site with the University of Michigan as the coordinating site for the A5 alliance, a multi-institutional collaborative designed to study neuroendocrine and adrenal tumors.

Trial Health

45
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
20mo left

Started Dec 2025

Typical duration for all trials

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress21%
Dec 2025Jan 2028

First Submitted

Initial submission to the registry

March 9, 2020

Completed
3 months until next milestone

First Posted

Study publicly available on registry

June 16, 2020

Completed
5.5 years until next milestone

Study Start

First participant enrolled

December 1, 2025

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2027

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2028

Last Updated

February 10, 2025

Status Verified

February 1, 2025

Enrollment Period

1.1 years

First QC Date

March 9, 2020

Last Update Submit

February 6, 2025

Conditions

Neuroendocrine TumorsAdrenal Tumor

Outcome Measures

Primary Outcomes (1)

  • Survival

    10 years

Secondary Outcomes (1)

  • Tumor Recurrence

    10 years

Study Arms (2)

Neuroendocrine Tumor

Other: No intervention

Adrenal Tumor

Other: No intervention

Interventions

No interventionOTHER

There are no interventions

Adrenal TumorNeuroendocrine Tumor

Eligibility Criteria

Age18 Years - 90 Years
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Patients diagnosed and seeking treatment for neuroendocrine tumors or adrenal tumors

You may qualify if:

  • diagnosed with neuroendocrine and/or an adrenal tumor

You may not qualify if:

  • pregnant women
  • prisoners
  • people under the age of 18

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITH DNA

Tumor specimens, blood and/or saliva samples

MeSH Terms

Conditions

Neuroendocrine TumorsAdrenal Gland Neoplasms

Condition Hierarchy (Ancestors)

Neuroectodermal TumorsNeoplasms, Germ Cell and EmbryonalNeoplasms by Histologic TypeNeoplasmsNeoplasms, Nerve TissueEndocrine Gland NeoplasmsNeoplasms by SiteAdrenal Gland DiseasesEndocrine System Diseases
0

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Target Duration
5 Years
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor of Surgery

Study Record Dates

First Submitted

March 9, 2020

First Posted

June 16, 2020

Study Start

December 1, 2025

Primary Completion (Estimated)

January 1, 2027

Study Completion (Estimated)

January 1, 2028

Last Updated

February 10, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will share